TORONTO and HOUSTON, April 25,
2018 /CNW/ - Medicenna Therapeutics Corp. ("Medicenna"
or the "Company") (TSX: MDNA; OTCQX: MDNAF), a clinical stage
immuno-oncology company, is pleased to announce that executives
from Medicenna, Dr. Fahar Merchant, Chairman, President and
CEO and Ms. Elizabeth Williams, CFO, will present an
overview of the Company at the Bloom Burton &
Co. Healthcare Investor Conference.
Details of the presentation are as follows:
|
Date:
|
Wednesday, May
2, 2018
|
|
Time:
|
11:00 am
ET
|
|
Location:
|
Hall B, Lower
Concourse Level of the Sheraton Centre Toronto
Hotel, Toronto, Canada
|
About the Conference:
The Bloom Burton & Co.
Healthcare Investor Conference brings together U.S., Canadian and
international investors who are interested in the latest
developments in the Canadian healthcare sector. Attendees will have
an opportunity to obtain corporate updates from the premier
Canadian publicly traded and private companies through
presentations and private meetings.
About Medicenna Therapeutics
Medicenna is a clinical
stage immuno-oncology company developing novel highly selective
versions of IL-2, IL-4 and IL-13 Superkines™ and first in class
Empowered Cytokines™ (ECs). Medicenna is specifically
targeting the Interleukin-4 Receptor (IL4R), which is
over-expressed by at least 20 different types of cancer affecting
more than one million new cancer patients every year. A Phase
2b clinical trial for recurrent
glioblastoma (rGBM) is enrolling patients at leading brain cancer
centres in the US using Medicenna's lead candidate MDNA55. MDNA55
has completed 3 clinical trials in 72 patients, including 66 adults
with rGBM, demonstrated compelling efficacy and obtained Fast-Track
and Orphan Drug status from USFDA. Unlike most other cancer
therapies, Medicenna's MDNA55 has the potential to purge both the
tumor and the immunosuppressive tumor microenvironment, offering a
unique treatment paradigm for a large majority of cancer
patients.
For more information, please visit www.medicenna.com.
View original
content:http://www.prnewswire.com/news-releases/medicenna-to-present-at-bloom-burton--co-healthcare-investor-conference-2018-300636067.html
SOURCE Medicenna Therapeutics Corp.